Download PDF
Exp Clin Endocrinol Diabetes 2015; 123(09): 567-570
DOI: 10.1055/s-0035-1564072
Article
© Georg Thieme Verlag KG Stuttgart · New York

Significance of MPV, RDW with the Presence and Severity of Metabolic Syndrome

R. Farah
1   Department of Internal Medicine B, Ziv Medical Center, Safed, Israel, Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel
,
R. Khamisy-Farah
2   Clalit Health Service, Western Galilee, Akko, Israel
› Author Affiliations
Further Information

Publication History

received 13 May 2015
first decision 13 May 2015

accepted 19 August 2015

Publication Date:
15 September 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Purpose: Metabolic syndrome (MS) is a multiplex risk factor that arises from insulin resistance accompanying abnormal adipose deposition and function. It is a risk factor for coronary heart disease, as well as for diabetes, fatty liver, and several cancers. Recent studies showed that there was a correlation between inflammatory mediators and MS. The aim of this study was to investigate the relationship between the MS and new inflammatory markers as mean platelet volume (MPV) and red blood cell distribution width (RDW), they are simple and reliable indicators of inflammation.

Method: 200 patients who met the MS criteria and other 100 age- and sex-matched control subjects were included in this randomized controlled trial. Patients were classified into 2 groups each 100 subjects based on the number of MS criteria: group 1 (patients with 3 MS criteria), group 2 (patients with 5 MS criteria). MPV and RDW were calculated from complete blood count.

Results: Patients with MS had significantly higher MPV and RDW correspondingly compared to those without MS. (MPV: 8.4±0.61 v 8.80±0.60, 9.56±0.48, respectively, p<0.001) (RDW:12.38±0.77, 13.15±062, 13.90±0.55). Moreover, patients meeting 5 MS criteria had higher MPV and RDW than those meeting 3 criteria (p<0.001) and 0.000, respectively)

Conclusion: The present study indicated, for the first time, a significant correlation between the 2 criteria of MS and inflammation based on these new markers that should be simple and reliable indicator of inflammation.

Key words

metabolic syndrome - MPV - RDW - inflammation
 

  • References

  • 1 Grundy SM, Brewer BH, Cleeman JI et al. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. NHLBI/AHA Conference Proceedings. Circulation 2004; 52: 433-438
    PubMedGoogle Scholar
  • 2 American Hearth Association . Treatment Panel III; Final Report on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel. Circilation 2002; 106: 3143-3421
    PubMedGoogle Scholar
  • 3 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Diagnosis, and Treatment of High Cholesterol in Adults: (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
    CrossrefPubMedGoogle Scholar
  • 4 Yudkin JS, Stehouwer CD, Emesis JJ et al. C-reactive protein in healthy subjects; associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999; 19: 972-978
    CrossrefPubMedGoogle Scholar
  • 5 Ridker PM, Buring JE, Cook NR et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003; 107: 391-397
    CrossrefPubMedGoogle Scholar
  • 6 Park BJ, Shim JY, Lee HR et al. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets 2012; 23: 45-50
    CrossrefPubMedGoogle Scholar
  • 7 Nechita A, Delcea C, Enache V et al. Metabolic syndrome and mean platelet volume variation in patients with chest pain and negative cardiac enzymes. J Med Life 2013; 6: 156-160
    PubMedGoogle Scholar
  • 8 Shah B, Sha D, Xie D et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999-2004. Diabetes Care 2012; 35: 1074-1078
    CrossrefPubMedGoogle Scholar
  • 9 Chu SG, Becker RC, Berger PB et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148-156
    CrossrefPubMedGoogle Scholar
  • 10 Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 1969; 48: 1083-1087
    CrossrefPubMedGoogle Scholar
  • 11 Martin JF, Trowbridge EA, Salmon G et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460
    CrossrefPubMedGoogle Scholar
  • 12 Jakubowski JA, Thompson CB, Vaillancourt R et al. Arachidonic acid metabolism by platelets of differing size. Br J Haematol 1983; 53: 503-511
    CrossrefPubMedGoogle Scholar
  • 13 Cameron HA, Phillips R, Ibbotson RM et al. Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 1983; 287: 449-451
    CrossrefPubMedGoogle Scholar
  • 14 Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-1411
    CrossrefPubMedGoogle Scholar
  • 15 Bath P, Algert C, Chapman N et al. PROGRESS Collaborative Group . Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622-626 Epub 2004 Feb 19
    CrossrefPubMedGoogle Scholar
  • 16 Magri CJ, Fava S. Red blood cell distribution width and diabetes-associated complications. Diabetes Metab Syndr 2014; 8: 13-17 DOI: 10.1016/j.dsx.2013.10.012. Epub 2013 Nov 16
    CrossrefPubMedGoogle Scholar
  • 17 Fujita B, Strodthoff D, Fritzenwanger M et al. Altered red blood cell distribution width in overweight adolescents and its association with markers of inflammation. Pediatr Obes 2013; 8: 385-391 DOI: 10.1111/j.2047-6310.2012.00111.x. Epub 2012 Dec 13
    CrossrefPubMedGoogle Scholar
  • 18 Tonelli M, Sacks F, Arnold M et al. for the Cholesterol and Recurrent Events (CARE) Trial Investigators . Relation between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation 2008; 117: 163-168
    CrossrefPubMedGoogle Scholar
  • 19 Cavusoglu E, Chopra V, Gupta A et al. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. Int J Cardiol 2010; 141: 141-146 DOI: 10.1016/j.ijcard.2008.11.187.
    CrossrefPubMedGoogle Scholar
  • 20 Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome-AHA/NHLBI Scientific Statement. Circulation 2005; 112: 2735-2752
    CrossrefPubMedGoogle Scholar
  • 21 Fröhlich M, Imhof A, Berg G et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000; 23: 1835-1839
    CrossrefPubMedGoogle Scholar
  • 22 Onat A, Avcı GS, Barlan MM et al. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28: 1018-1025
    CrossrefPubMedGoogle Scholar
  • 23 Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alfa in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200
    CrossrefPubMedGoogle Scholar
  • 24 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alfa: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
    CrossrefPubMedGoogle Scholar
  • 25 Ridker PM, Buring JE, Cook NR et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003; 107: 391-397
    CrossrefPubMedGoogle Scholar
  • 26 Haffner SM. The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006; 97 (Suppl) 3A-11A
    PubMedGoogle Scholar
  • 27 Kressel G, Trunz B, Bub A et al. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis 2009; 202: 263-271
    CrossrefPubMedGoogle Scholar
  • 28 Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87: 1067-1075
    CrossrefPubMedGoogle Scholar
  • 29 Papa A, Emdin M, Passino C et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 2008; 395: 27-31
    CrossrefPubMedGoogle Scholar
  • 30 Avanzas P, Arroyo-Espliguero R, Cosin-Sales J et al. Markers of inflammation and multiple complex stenosis (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 2004; 90: 847-852
    CrossrefPubMedGoogle Scholar